{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorder&page=2",
    "query": {
      "condition": "Growth Disorder",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorder&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T02:43:18.969Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06538038",
      "title": "Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Epidermal Growth Factor Receptor Gene Mutation",
        "Stage III Lung Cancer",
        "Stage IV Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib + Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PrECOG, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 538,
      "start_date": "2024-09-17",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 146,
      "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Emeryville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06538038"
    },
    {
      "nct_id": "NCT00008385",
      "title": "Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "selenium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1772,
      "start_date": "2000-12-18",
      "completion_date": "2019-11",
      "has_results": true,
      "last_update_posted_date": "2023-07-05",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 515,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 339 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00008385"
    },
    {
      "nct_id": "NCT02525029",
      "title": "Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Pregnyl®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "Up to 76 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-03",
      "completion_date": "2022-04",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02525029"
    },
    {
      "nct_id": "NCT01563445",
      "title": "Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Intracerebral Haemorrhage"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2001-11",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01563445"
    },
    {
      "nct_id": "NCT04176757",
      "title": "A Study of ZN-c5 in Participants With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ZN-c5",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zeno Alpha Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2020-01-03",
      "completion_date": "2021-05-25",
      "has_results": false,
      "last_update_posted_date": "2022-08-01",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • New York, New York • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04176757"
    },
    {
      "nct_id": "NCT00317772",
      "title": "Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Neoplasms",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 19,
      "start_date": "2004-09-02",
      "completion_date": "2020-11-04",
      "has_results": true,
      "last_update_posted_date": "2022-02-07",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00317772"
    },
    {
      "nct_id": "NCT02846766",
      "title": "Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teresa Helsten, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-07-01",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2018-08-02",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Chicago, Illinois",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846766"
    },
    {
      "nct_id": "NCT00371657",
      "title": "Maternal Obesity and Small for Gestational Age Infants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Small for Gestational Age"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Oklahoma State University Center for Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 420,
      "start_date": "2006-07",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2008-02-04",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00371657"
    },
    {
      "nct_id": "NCT00561340",
      "title": "Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Pediasure",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Nutritional counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "5 Years to 9 Years"
      },
      "enrollment_count": 29,
      "start_date": "2006-01-02",
      "completion_date": "2010-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-04",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00561340"
    },
    {
      "nct_id": "NCT00271518",
      "title": "Treatment of Children With Insufficient Secretion of Growth Hormone",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Deficiency (GHD)"
      ],
      "interventions": [
        {
          "name": "growth hormone (somatropin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LG Life Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "3 Years to 11 Years"
      },
      "enrollment_count": 144,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-03-17",
      "last_synced_at": "2026-06-11T02:43:18.969Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00271518"
    }
  ]
}